Avivagen Inc.

102 articles about Avivagen Inc.

• Avivagen Provides Corporate Updates - July 31, 2023

  7/31/2023

  Avivagen Inc. announces several corporate updates, relating to the allowances of patents, a waiver of an interest payment on its senior secured debentures and the continuation of the strategic review process.

• Avivagen Announces New Orders for 1.1 Tonnes of Oxc-Beta™ Livestock Product

  7/24/2023

  Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce two orders for OxC-beta™.

• Avivagen Inc. Announces Results for the Second Quarter Ending April 30, 2023

  6/6/2023

  Avivagen Inc. has announced its unaudited financial results for the Second quarter of 2023.

• Avivagen Announces Significant Increase in Sales to an Existing Customer

  5/25/2023

  Avivagen Inc. is pleased to announce that an existing customer has placed an order sized at 400% of its normal monthly order volume.

• Avivagen Inc. Provides Update on Securities for Service Agreements With CEO and CSO

  3/29/2023

  Avivagen Inc. announces that pursuant to its previously announced “Securities for Services” agreements with Top Meadow Consulting Services Inc. and Mr. Graham Burton, the Company has issued an aggregate of 507,345 common shares in the capital of the Company to Top Meadow Consulting Services Inc. and Mr. Graham Burton.

• Avivagen Inc. Announces Results for the First Quarter Ending January 31, 2023

  3/17/2023

  Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the first quarter of 2023.

• Avivagen Reports Fiscal Year 2022 Financial Results and Strategic Initiatives to Accelerate Growth

  2/21/2023

  Avivagen Inc. today reported its audited financial results for the year ended October 31, 2022 and the implementation of a strategic plan to accelerate growth.

• Avivagen Announces Foundational Scientific and Commercial Evidence of OxC-Beta™ Product Published in Peer-Reviewed Journal

  1/19/2023

  Avivagen Inc. is pleased to announce that its scientific team has just published a peer-reviewed paper describing the discovery, natural occurrence, scientific significance, commercial livestock applications and safety of OxBC, the active ingredient of OxC-beta™ Livestock.

• Avivagen Inc. Announces Securities for Service Agreements With CEO and CSO

  12/22/2022

  Avivagen Inc. announces that, pursuant to Policy 4.4 of the TSX Venture Exchange, it has entered into a “securities for services” agreement with each of Top Meadow Consulting Services Inc. and Mr. Graham Burton, pursuant to which the Company may elect to settle up to 15% of the fees or salary of such persons in common shares of the Company for the period from October 1, 2022 to February 28, 2023.

• Avivagen Inc. Announces Closing of Second Tranche of a Private Placement of Shares

  10/31/2022

  Avivagen Inc. announces that it has closed the second tranche of its previously announced non-brokered private placement financing through the issuance of common shares of the Company at a price of $0.20 per Share (for more information about the Offering and the first tranche thereunder, please see the Company’s news release dated October 21, 2022 for more details.

• Avivagen Inc. Announces Results for the Third Quarter Ending July 31, 2022

  9/16/2022

  Avivagen Inc. has announced its unaudited financial results for the third quarter of 2022.

• Avivagen Announces Publication of Peer-Reviewed Article in Food and Chemical Toxicology Journal

  9/7/2022

  Avivagen Inc. is pleased to announce that its scientific paper entitled “Safety and uptake of fully Oxidized Beta Carotene” has been published in the Journal of Food and Chemical Toxicology.

• Avivagen Announces New Dairy Customer in Mexico

  8/19/2022

  Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce it has secured a promising new customer in the Mexican dairy industry.

• Avivagen Announces Receipt of Repeat Order from Asian Customer

  8/11/2022

  Avivagen Inc. is pleased to announce that one of its most important customers in Asia has placed a new order for four tonnes of OxC-BetaTM Livestock to be used in Asia, in line with previous shipments fulfilled in 2021.

• Avivagen Announces Significant Order of OxC-beta™  in Brazil

  8/3/2022

  Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce it has secured a significant order for OxC-beta™ from AB Vista.

• Avivagen Announces Sales of Companion Animal Product and Management Change

  7/29/2022

  Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce significant new and expanded sales of the company’s companion animal products.

• Avivagen Inc. Announces Closing of Third Tranche of a Private Placement of Shares and Warrants

  7/7/2022

  Avivagen Inc. announces that it has closed the third tranche of its previously announced non-brokered private placement financing through the issuance of units of the Company at a price of $0.20 per Unit .

• Avivagen Announces Successful Completion of Formal Safety and Toxicology Evaluation of Fully Oxidized Beta-Carotene (OxBC)

  6/9/2022

  Avivagen Inc. is pleased to announce that it has completed a series of important safety evaluations of fully oxidized beta-carotene, the proprietary and critical active ingredient in the company’s highly-regarded OxC-beta™ product line.

• Avivagen Signs New Distribution Partner in Vietnam to Support Southeast Asian Growth

  5/30/2022

  Avivagen Inc. is pleased to announce that it has signed a new distribution agreement with Nong San Viet Co., Ltd to support the company’s continued market expansion for its oxidized carotenoid-based feed additive product in Vietnam.

• Avivagen Announces AGM Results and Update to Shareholders - Apr 08, 2022

  4/8/2022

  Avivagen Inc. announced the results of its annual general meeting of shareholders and highlighted the significant progress made in the Corporation’s efforts to drive further adoption of OxC-betaTM worldwide.